SSK1,是一种衰老特异性杀伤化合物,是一种 β-galactosidase 靶向前药,可减轻炎症。SSK1 被溶酶体 β-galactosidase 激活,并通过激活p38 MAPK和诱导细胞凋亡 (apoptosis) 选择性杀死衰老细胞。
生物活性 | SSK1, a senescence-specific killing compound, is a β-galactosidase-targeted prodrug attenuates inflammation. SSK1 is activated by lysosomal β-galactosidase and selectively killed senescent cells through the activation ofp38 MAPKand induction ofapoptosis[1]. |
体外研究 (In Vitro) | SSK1 (0.5 μM; 12-72 hours) activates the phosphorylation levels of both p38 MAPK and MKK3/MKK6 in senescent cells. SSK1 kills senescent cells through the activation of the p38 MAPK signaling pathway. SSK1 is able to induce mitochondrial DNA damage in senescent cells[1]. SSK1 (0.01-1 μM; 3 days) selectively and potently eliminates β-galactosidase-positive senescent cells within a wide therapeutic window[1].
Cell Proliferation Assay[1] Cell Line: | Primary mouse fibroblasts | Concentration: | 0.5 μM | Incubation Time: | 12 hours, 24 hours, 36 hours, 48 hours, 72 hours | Result: | Both p38 MAPK and MKK3/MKK6 were activated by phosphorylation in senescent cells. |
|
体内研究 (In Vivo) | SSK1 (0.5 mg/kg; i.p.; two days every week; for four weeks) could eliminate senescent cells and decrease senescence-associated markers in lung-injured mice[1]. In aged mice (20-month-old), SSK1 (0.5 mg/kg; 3 days every 2 weeks for 8 weeks) effectively clears senescent cells in different tissues, decreases the senescence- and age-associated gene signatures, attenuates low-grade local and systemic inflammation, and restores physical function[1].
Animal Model: | Mice (3-6-month-old) were subjected to transtracheal injection of Bleomycin[1] | Dosage: | 0.5 mg/kg | Administration: | Intraperitoneally injection; two days every week; for four weeks | Result: | SSK1 significantly reduced the percentage of SA-β-gal-positive cells in lung by 3.8-fold compared with that in vehicle-treated lung-injured mice |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
溶解性数据 | In Vitro: DMSO : 200 mg/mL(253.61 mM;Need ultrasonic) 配制储备液 1 mM | 1.2681 mL | 6.3403 mL | 12.6805 mL | 5 mM | 0.2536 mL | 1.2681 mL | 2.5361 mL | 10 mM | 0.1268 mL | 0.6340 mL | 1.2681 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture and light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 5 mg/mL (6.34 mM); Clear solution
此方案可获得 ≥ 5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 5 mg/mL (6.34 mM); Clear solution
此方案可获得 ≥ 5 mg/mL (6.34 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|